ICU Medical (ICUI) is an $892 million small-cap producer of innovative medical devices that are used in infusion therapy, oncology, and critical care. The company's products help to prevent bloodstream infections and protect healthcare workers from accidental needle stick injuries and hazardous drugs. It also produces critical care devices that are used for monitoring continuous cardiac output, oxygen saturation, and other key measures to diagnose and treat critical care patients.
The company's CLAVE product is a one-piece needle-free infusion device. The CLAVE products accounted for 36% of ICU Medical's revenue in 2011.
ICU Medical's largest customer is Hospira Inc. (HSP), which accounted for 41% of worldwide revenue for the first nine months of 2012. It also sells to other medical product manufacturers, independent distributors, and through direct sales to end users.
I think that ICU Medical could be a possible takeover target as a larger company could expand the reach for the company's products and take them to the next level for increased revenue and earnings. ICUI is currently trading at only 2.31 times its book value per share. When the price to book ratio is under 3, companies are typically attractively valued.
Some possible buyers for ICUI would be Becton Dickinson and Company (BDX), Baxter International (BAX), or Covidien plc (COV). All three of these companies have sufficient cash to cover the cost of acquiring ICUI.
Operating Cash Flow (TTM)
An acquisition of ICUI would help expand and enhance the business of these possible suitors.
ICU Medical has a profit margin of 15% and operating cash flow of $69.37 million. It has $204 million in total cash with zero debt. The company also has an impressive current ratio of 10.81.
The demographics of the aging baby boomers also favor ICU Medical. With 10,000 baby boomers turning 65 every day, the need for the company's products will increase as the health of large numbers of seniors deteriorates.
Regardless of whether it is taken over, ICUI stands on its own as an attractive investment. It has 6 positive earnings revisions for 2012 and 4 upward revisions for 2013. The company is expected to grow earnings annually at 10.17% for the next five years. These estimates should be easily met. This growth should reasonably allow the current stock price of $61 to reach about $100 in five years.